New combo therapy aims to shrink tumors, cut harsh treatment for HPV-Linked throat cancer
NCT ID NCT05108870
Summary
This study is testing whether adding two new, experimental drugs (HB-201 and HB-202) to standard chemotherapy can better shrink tumors in people with HPV16-positive throat cancer. The goal is to see if this stronger initial treatment allows doctors to safely use less radiation or chemotherapy later, potentially reducing side effects. Researchers will also monitor safety and track how well the cancer responds over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.